Pomalidomide-C2-NH2 hydrochloride is primarily utilized in the development of targeted cancer therapies. It serves as a key intermediate in the synthesis of more complex molecules designed to treat multiple myeloma and other hematologic malignancies. Its structure allows for modifications that enhance binding affinity to specific cellular targets, improving therapeutic efficacy. This compound is particularly valuable in research focused on immunomodulatory drugs, where it contributes to the inhibition of tumor growth and the modulation of the immune response. Additionally, it is employed in preclinical studies to evaluate its potential in combination therapies, aiming to overcome drug resistance in cancer treatment.